Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
NCT06788626 on ClinicalTrials.gov · last registry update 2025-01-23
Registered but not yet open, with 390 participants planned. Due to report February 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: The ordinal shift of modified Rankin Scale. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Wei Hu
- Sponsor type
- Other
- Enrollment
- 390
- Started
- 2025-02
- Primary completion
- 2028-02 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The ordinal shift of modified Rankin Scale
Conditions studied
Acute Ischemic Stroke · Large Vessel Occlusion · Neuroprotective Drugs · Endovascular Treatment
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.